

NICE Technology Appraisals About Medicines: Formulary Adherence

Technology appraisal (TA) are hyperlinks to full guidance	Titles	Date of TA Release	Availability of medicine for NHS patients with this medical condition, as indicated by NICE	Adherence of local formulary to NICE	
				Included on the Trust Formulary for this indication Yes OR No	Reason provided if "No"
2008-09					
Renal cell carcinoma - sunitinib (TA169)		31/03/2009	Sunitinib – a recommended first line option for mobile people with advanced and/or metastatic disease if immunotherapy suitable.	Yes	
Influenza (treatment) - zanamivir, amantadine and oseltamivir (review) (TA168)		28/02/2009	Note national guidance on flu jabs. For flu that is not a widespread epidemic: Oseltamivir, zanamivir – a recommended option in ‘at risk’ people in specified circumstances. Amantadine – not recommended to treat flu.	No	This medicine is not applicable to C&W
Hyperuricaemia - febuxostat (TA164)		31/12/2008	Febuxostat – recommended option for chronic hyperuricaemia in gout if allopurinol unsuitable or not tolerated.	Yes	
Ulcerative colitis (acute exacerbations) - infliximab (TA163)		31/12/2008	Infliximab – a recommended option in severely active ulcerative colitis if ciclosporin inappropriate, or as part of a clinical trial.	Yes	
Lung cancer (non-small-cell) - erlotinib (TA162)		30/11/2008	Erlotinib – recommended if one previous chemotherapy regimen ineffective, as cost neutral alternative to docetaxel. Not recommended in locally advanced or metastatic NSCLC after one prior unsuccessful regimen when docetaxel unsuitable. Not recommended after two prior unsuccessful regimens, including docetaxel.	Yes	
Influenza (prophylaxis) - amantadine, oseltamivir and zanamivir (TA158) Including review of TA67		30/09/2008	Note national guidance on flu jabs. For flu that is not a widespread epidemic: Oseltamivir, zanamivir – a recommended option in non-vaccinated, flu-exposed, ‘at risk’ people in specified circumstances. Amantadine – not recommended to prevent flu.	No	This medicine is not applicable to C&W
Venous thromboembolism - dabigatran (TA157)		30/09/2008	Dabigatran etexilate – recommended option to reduce VTE risk after hip or knee replacement surgery.	Yes	
Macular degeneration (age-related) - ranibizumab and pegaptanib (TA155)		31/08/2008	Ranibizumab – a recommended option for deteriorating wet AMD in specified circumstances. Pegaptanib – not recommended for wet AMD.	Yes	
Pregnancy (rhesus negative women) - routine anti-D (review) (TA156)		31/08/2008	Anti-D immunoglobulin – a recommended antenatal option for RhD negative pregnant women who are not known to be 'sensitised'.	Yes	
Hepatitis B - telbivudine (TA154)		31/08/2008	Telbivudine – not recommended for chronic hepatitis B.	Yes	

Hepatitis B - entecavir (TA153)	31/08/2008	Entecavir – a recommended option for chronic hepatitis B.	Yes	
Head and neck cancer - cetuximab (TA145)	30/06/2008	Cetuximab – a recommended option with radiotherapy for locally advanced squamous cell disease with Karnofsky score 90% or more, and if platinum-based chemotherapy inappropriate.	No	This medicine is not applicable to C&W
Psoriasis - adalimumab (TA146)	30/06/2008	Adalimumab – a recommended option for severe plaque psoriasis if other treatments are unsuitable, unsuccessful or not tolerated.	Yes	
Glioma (recurrent) - carmustine implants (terminated appraisal) (TA149)	30/06/2008	Gefitinib – unable to recommend NHS use as an adjunct to surgery. TA terminated due to lack of evidence submission.	No	NICE are unable to recommend this medicine for this indication
Lung cancer (non-small-cell) - bevacizumab (terminated appraisal) (TA148)	30/06/2008	Bevacizumab – unable to recommend NHS use with platinum-based chemotherapy for unresectable non-small-cell lung cancer (other than predominantly squamous cell histology). TA terminated due to lack of evidence submission.	Yes	
Anaemia (cancer-treatment induced) - erythropoietin (alpha and beta) and darbepoetin (TA142)	31/05/2008	Erythropoietin analogues with iron injections – a recommended option for profound anaemia after chemotherapy if blood transfusions cannot be given; and after platinum-based chemotherapy for ovarian cancer if haemoglobin is 8 g/100 ml or less.	Yes	
Ankylosing spondylitis - adalimumab, etanercept and infliximab (TA143)	31/05/2008	Adalimumab, etanercept – recommended options for severe ankylosing spondylitis if at least 2 NSAIDs ineffective. The other drug may be tried if the first is not tolerated, but not if it is ineffective. Infliximab – not recommended.	Yes	
Ulcerative colitis (subacute manifestations) - infliximab (TA140)	30/04/2008	Infliximab – not recommended for subacute, moderate to severely active ulcerative colitis as specified.	Yes	